Biotech Values

[NP1986]

I would respectfully submit that it's going to take a whole lot more than this $90M opportunity to justify current valuation, let alone provide meaningful upside to the valuation

IMO, there is significant upside if you consider that based on PACE, ponatinib's label is likely to be broader than the patient populations I described. For me, T315I and failures on both Sprycel and Tasigna represent the "floor" and the patient populations where I think ponatinib is most likely to succeed. If you include patients failing just one second generation TKI, the potential market size increases substantially (even when taking into account the advent of generic Gleevec, there is a substantial number of patients on Sprycel or Tasigna who are likely to fail eventually ).